CD274 and neoplasm: In the RATIONALE-307 study, TIS was found to predict the PFS benefit of tislelizumab combined with chemotherapy in advanced NSCLC [112], integrating the expression of PD-L1 in circulating leukocytes, platelets, and platelet particles and the expression biomarker of PD-L1 in tumor cells can better distinguish patients who may benefit from immunotherapy [113].